Loading...Loading...Johnson & Johnson JNJ is reporting its second-quarter earnings on Wednesday. Wall Street expects $2.7 in EPS and $22.3 billion in revenues as the company reports before market hours.The stock is down 5.56% over the past year, -4.16% YTD.Let’s look at what the charts indicate for Johnson & Johnson stock and how the stock currently maps against Wall Street estimates.Johnson & Johnson Technical Setup Ahead Of Q2 Earnings Johnson & Johnson stock is exhibiting a strongly bullish trend, as its ...

Loading...Loading...Johnson & Johnson JNJ will release its second-quarter financial results, before the opening bell on Wednesday, July 17.Analysts expect the New Brunswick, New Jersey-based company to report quarterly earnings at $2.70 per share, up from $2.56 per share in the year-ago period. Johnson & Johnson is expected to post revenue of $22.29 billion, compared to $25.53 billion a year earlier, according to data from Benzinga Pro.Emergent BioSolutions Inc EBS, through its subsidiary Emergent Manufactu ...

GERMANY - 2024/02/16: In this photo illustration, a Johnson & Johnson logo seen displayed on a ... [+] tablet. (Photo Illustration by Igor Golovnov/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesJohnson & Johnson stock (NYSE: JNJ) will report its Q2 2024 results on Wednesday, July 17. We expect the company to post revenue of $22.5 billion and earnings of $2.72 per share, broadly aligning with the consensus estimates of $22.4 billion and $2.71, respectively. J&J will likely ...

Johnson & Johnson (JNJ) will report its second-quarter 2024 earnings on Jul 17. The Zacks Consensus Estimate for second-quarter sales and earnings is pegged at $22.38 billion and $2.71 per share, respectively. Earnings estimates for JNJ have declined from $10.64 per share to $10.50 per share for 2024 and from $10.92 per share to $10.86 per share for 2025 over the past 60 days.JNJ Estimate MovementImage Source: Zacks Investment ResearchEarnings Surprise HistoryThe healthcare bellwether’s performance has been ...

SANTA ANA, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapeutics, today announced the appointment of Dr. Marco Gottardis as a director and member of the Company's Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee, effective July 11, 2024. Dr. Got ...

They don't have the most exciting businesses, but they have a lot to offer nonetheless.Healthcare never sleeps. There is always demand for medical services, regardless of the state of the economy. Companies that offer these necessary goods and are innovative enough to keep up with the changing trends in the sector tend to last. That describes Johnson & Johnson (JNJ 0.12%) and Medtronic (MDT -0.15%) well. Both are among the largest healthcare companies in the world, have proven innovative abilities, and have ...

Group 1: Earnings Season Overview - The 2024 Q2 earnings season is underway, with positive expectations for the S&P 500 to show earnings growth [1] - Key reports to watch include those from Netflix, Taiwan Semiconductor, and Johnson & Johnson [1] Group 2: Netflix - Netflix is set to report quarterly results on July 18, with shares recovering to near all-time highs after a previous earnings drop [2] - Total subscribers reached 269.6 million, marking a 16% year-over-year increase, with four consecutive beats in subscriber additions [2] - Earnings per share (EPS) is expected to grow by 43% on 17% higher sales, reflecting improved profitability and higher margins [3] Group 3: Taiwan Semiconductor - Taiwan Semiconductor (TSM) shares have increased over 80% in 2024, driven by the AI chip demand [5] - Earnings estimate for the quarter is $1.37 per share, indicating a 20% increase year-over-year, while sales are expected to reach $20.2 billion, up 5% [5] - TSM announced a 10% increase in its quarterly payout to $0.45 per share, appealing to income-focused investors [7] Group 4: Johnson & Johnson - Johnson & Johnson has seen stagnant share performance over the last three years, with a 4% overall loss, but has consistently exceeded EPS estimates [8] - The Zacks Consensus EPS estimate for the upcoming release is $2.71, down 1% since mid-April, with revenue expectations at $22.4 billion, suggesting a 12% decline year-over-year [9] - JNJ is scheduled to report on July 17, before market opens [9]

Core Insights - Johnson & Johnson (JNJ) is expected to report quarterly earnings of $2.71 per share, reflecting a decline of 3.2% year over year, with revenues forecasted at $22.38 billion, a decrease of 12.3% year over year [1] - Analysts have revised the consensus EPS estimate down by 0.3% over the last 30 days, indicating a reassessment of initial forecasts [1] - The relationship between earnings estimate trends and short-term stock price movements is well-documented [1] Sales Projections - Analysts project 'Sales- MedTech- Total' to reach $8.21 billion, indicating a year-over-year increase of 5.4% [2] - 'Sales- Innovative Medicine- WW' is expected to be $14.18 billion, reflecting a 3.2% increase year over year [2] - 'Sales- MedTech- Orthopaedics- Trauma- WW' is estimated at $764.77 million, showing a 3.5% increase from the previous year [2] Detailed Sales Estimates - 'Sales- MedTech- Orthopaedics- Spine, Sports & Other- WW' is projected at $780.35 million, a 1.9% increase year over year [3] - 'Sales- MedTech- Orthopaedics- Hips- US' is expected to be $261.14 million, indicating a 4.5% increase [3] - 'Sales- MedTech- Orthopaedics- Hips- International' is forecasted at $146.40 million, reflecting a slight decline of 0.4% [3] - 'Sales- MedTech- Orthopaedics- Knees- US' is estimated at $226.07 million, a 2.3% increase [3] - 'Sales- MedTech- Orthopaedics- Knees- International' is projected at $149.67 million, indicating a 5.4% increase [3] Additional Sales Insights - 'Sales- MedTech- Orthopaedics- Trauma- US' is expected to reach $498.64 million, a 3.2% increase year over year [4] - 'Sales- MedTech- Orthopaedics- Trauma- International' is projected at $267.83 million, reflecting a 5% increase [4] - 'Sales- MedTech- Orthopaedics- Spine, Sports & Other- US' is estimated at $440.94 million, indicating a 1.8% increase [4] - Organic Sales Growth (Operational growth) is expected to be 4.9%, down from 7.5% in the same quarter last year [4] Stock Performance - Johnson & Johnson shares have increased by 2.9% over the past month, compared to a 4.3% increase in the Zacks S&P 500 composite [4]

Core Viewpoint - The article emphasizes the importance of recession-proof stocks as a safe investment strategy amid potential economic downturns, highlighting companies with strong fundamentals and operational efficiency that can thrive during challenging times [1] Group 1: Walmart (WMT) - Walmart is recognized as a leading big-box retailer, benefiting from its low-price strategy, especially during inflationary periods, with a year-over-year growth of 5.7%, surpassing its 5-year average by 22% [2] - The stock has appreciated over 30% year-to-date, making it a strong candidate for a recession-resistant portfolio, alongside a recent 9% dividend increase, marking 50 years of consecutive dividend growth [2] - In Q1 of fiscal 2025, Walmart reported a 6% year-over-year sales increase, driven by significant growth in eCommerce (21%) and advertising (24%), with adjusted earnings per share rising from 49 to 60 cents, a 22.4% increase year-over-year [3] Group 2: Johnson & Johnson (JNJ) - Johnson & Johnson, a major player in the healthcare sector for 138 years, has a strong focus on research, development, and manufacturing of healthcare products [4] - The company has a remarkable track record with 62 consecutive years of dividend growth, recently announcing a dividend increase with a forward yield exceeding 3.3% [5] - In its latest quarter, Johnson & Johnson reported $21.4 billion in sales, a 2.3% increase from the previous year, primarily driven by U.S. sales, and generated $24.3 billion in trailing twelve-month free cash flows, indicating strong financial health [5] Group 3: Procter & Gamble (PG) - Procter & Gamble is a leading consumer goods company known for its extensive product lineup, including brands like Tide and Gillette, demonstrating resilience and adaptability in a competitive market [6] - The company has a strong history of rewarding shareholders, with 68 consecutive years of dividend payouts, reflecting its operational strength [6] - In Q3, Procter & Gamble achieved net sales of $20.2 billion and an 11% year-over-year increase in earnings per share, with impressive net income and levered free cash flow margins of 18% and 14.6%, respectively [7]

Core Viewpoint - Johnson & Johnson (JNJ) is set to release its Q2 2024 earnings, with analysts expecting adjusted EPS of $2.69, reflecting a 3.9% decline year-over-year. The company has a strong track record of meeting earnings estimates, but significant deviations between reported and adjusted earnings raise questions about earnings quality and management practices [1][2][13]. Earnings Expectations - Analysts project JNJ's full-year adjusted EPS to be $10.54, a 6.3% increase year-over-year, leading to a forward P/E ratio of 14.2. JNJ management has provided a slightly higher midpoint guidance of $10.65, indicating a 7.4% growth [2][13]. - The company has experienced minimal earnings revisions over the past six months, which is typical for JNJ [2]. Earnings Quality and Adjustments - Over the past decade, JNJ's adjusted EPS has averaged 46% higher than reported EPS, with significant adjustments noted in years such as 2023 (+91%), 2022 (+51%), 2019 (+54%), and 2017 (+1,453%) [5][13]. - Major adjustments in 2023 included litigation costs (nearly 50% of total adjustments) and $4.5 billion in amortization of intangible assets. The company also adjusted for COVID-19 vaccine costs, which some analysts find inappropriate [7][8][13]. Impact of Kenvue Split-off - Concerns about JNJ's diversification arose following the split-off of its consumer healthcare division, Kenvue Inc. However, the level of diversification is not believed to be materially impaired, although earnings volatility may have increased [2][13]. Future Outlook - The decline in estimated amortization expenses for the coming years suggests a potentially weak pipeline for JNJ, which could impact future earnings power [8][13]. - Despite the adjustments, JNJ's strong balance sheet and credit rating (Aaa) indicate that the earnings adjustments are unlikely to stem from deeper financial issues [13].